{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T02:45:03Z","timestamp":1788749103582,"version":"build-2803163510"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["NO. 2022NSFSC1347"],"award-info":[{"award-number":["NO. 2022NSFSC1347"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Esophageal cancer (EC) is an aggressive malignancy raising a healthcare concern worldwide. Standard treatment options include surgical resection, chemotherapy, radiation therapy, and targeted molecular therapy. The five-year survival rate for all stages of EC is approximately 20%, ranging from 5% to 47%, with a high recurrence rate and poor prognosis after treatment. Immunotherapy has shown better efficacy and tolerance than conventional therapies for several malignancies. Immunotherapy of EC, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy, has shown clinical advantages. In particular, monoclonal antibodies against PD-1 have a satisfactory role in combination therapy and are recommended for first- or second-line treatments. Here, we present a systematic summary and analysis of immunotherapy-based combination therapies for EC.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1020290","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T06:47:01Z","timestamp":1671086821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Immune-based combination therapy for esophageal cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Huiling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengli","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14740338.2021.1955100","article-title":"The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy","volume":"21","author":"Ikeda","year":"2022","journal-title":"Expert Opin Drug Safety"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6797","DOI":"10.1038\/s41598-017-07071-5","article-title":"Time trends of esophageal and gastric cancer mortality in China, 1991\u20132009: an age-period-cohort analysis","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1314530","article-title":"Esophageal carcinoma","volume":"371","author":"Rustgi","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31462-9","article-title":"Oesophageal cancer","volume":"390","author":"Lagergren","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00300","article-title":"The combination options and predictive biomarkers of PD-1\/PD-L1 inhibitors in esophageal cancer","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7337","article-title":"Emerging multimodality approaches to treat localized esophageal cancer","volume":"17","author":"Kelly","year":"2019","journal-title":"J Natl Compr Cancer Network"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00866","article-title":"Treatment of locally advanced esophageal carcinoma: ASCO guideline","volume":"38","author":"Shah","year":"2020","journal-title":"JCO."},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5387\/fms.2018-09","article-title":"Immunotherapy for esophageal squamous cell carcinoma: a review","volume":"64","author":"Mimura","year":"2018","journal-title":"FJMS."},{"key":"B12","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","article-title":"Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment","volume":"11","author":"Zheng","year":"2020","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"118636","DOI":"10.1016\/j.ijpharm.2019.118636","article-title":"Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy","volume":"570","author":"Bai","year":"2019","journal-title":"Int J Pharmaceutics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Canc"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-15-3266-5_9","article-title":"Functions of immune checkpoint molecules beyond immune evasion","volume-title":"Regulation of cancer immune checkpoints: Molecular and cellular mechanisms and therapy","author":"Zhang","year":"2020"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Canc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J immunother canc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01425-7","article-title":"Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers","volume":"125","author":"Baxter","year":"2021","journal-title":"Br J Canc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Canc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.020","article-title":"Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives","volume":"59","author":"Moehler","year":"2016","journal-title":"Eur J Canc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30181-X","article-title":"Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial","volume":"18","author":"Kudo","year":"2017","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: The phase 2 KEYNOTE-180 study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00601","article-title":"Impact of pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer on health-related quality of life in KEYNOTE-181","volume":"40","author":"Adenis","year":"2022","journal-title":"JCO."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz422.002","article-title":"KEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced\/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"JCO."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.9846","article-title":"Safety and antitumor activity of the anti\u2013programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma","volume":"36","author":"Doi","year":"2018","journal-title":"JCO."},{"key":"B32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non\u2013Small-Cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"JCO."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-021-00850-0","article-title":"Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1\/ONO-4538-07)","volume":"18","author":"Satoh","year":"2021","journal-title":"Esophagus."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.204","article-title":"Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy","volume":"39","author":"Chin","year":"2021","journal-title":"JCO"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Canc"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1815","article-title":"Vaccines for tumour prevention","volume":"6","author":"Lollini","year":"2006","journal-title":"Nat Rev Canc"},{"key":"B46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1146\/annurev-cancerbio-030617-050558","article-title":"Prophylactic vaccines for nonviral cancers","volume":"2","author":"Scott","year":"2018","journal-title":"Annu Rev Cancer Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399407000221","article-title":"Age-related changes in immunity: implications for vaccination in the elderly","volume":"9","author":"Kovaiou","year":"2007","journal-title":"Expert Rev Mol Med 2007\/02\/01 Ed"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nri1150","article-title":"Cancer vaccines: between the idea and the reality","volume":"3","author":"Finn","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","article-title":"The changing landscape of therapeutic cancer vaccines\u2013novel platforms and neoantigen identification","volume":"27","author":"Jou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.703517","article-title":"The clinical application of neoantigens in esophageal cancer","volume":"11","author":"Gu","year":"2021","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: Current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.12.3.15949","article-title":"Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy","volume":"12","author":"Forghanifard","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4081\/ejh.2011.e7","article-title":"MAGE-A3\/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma","volume":"55","author":"Bujas","year":"2011","journal-title":"Eur J Histochem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02840-3","article-title":"Expression of cancer\u2013testis antigens in esophageal cancer and their progress in immunotherapy","volume":"145","author":"Zhang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/1479-5876-11-246","article-title":"Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients","volume":"11","author":"Kageyama","year":"2013","journal-title":"J Trans Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02892-w","article-title":"Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients","volume":"70","author":"Ishikawa","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25955","article-title":"A phase I study of vaccination with NY-ESO-1f peptide mixed with picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen","volume":"129","author":"Kakimi","year":"2011","journal-title":"Int J Canc"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-008-0568-4","article-title":"Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters","volume":"58","author":"Engell-Noerregaard","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2846","article-title":"Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine","volume":"46","author":"NARITA","year":"2015","journal-title":"Int J Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8734","article-title":"Pilot study of WT1 peptide\u2212pulsed dendritic cell vaccination with docetaxel in esophageal cancer","volume":"16","author":"Matsuda","year":"2018","journal-title":"Oncol Lett"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13542","article-title":"Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer","volume":"24","author":"Ogasawara","year":"2020","journal-title":"Ther Apher Dial"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003880","article-title":"Phase II adjuvant cancer-specific vaccine therapy for esophageal cancer patients curatively resected after preoperative therapy with pathologically positive nodes; possible significance of tumor immune microenvironment in its clinical effects","volume":"275","author":"Yasuda","year":"2022","journal-title":"Ann Surg"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02619-3","article-title":"Exploratory open-label clinical study to determine the s-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients","volume":"69","author":"Daiko","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01200.x","article-title":"Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer","volume":"100","author":"Kono","year":"2009","journal-title":"Cancer Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: A voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763806","article-title":"Genetically modified T cells for esophageal cancer therapy: A promising clinical application","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-016-0367-1","article-title":"T-Cell receptor-engineered T cells for cancer treatment: current status and future directions","volume":"9","author":"Ping","year":"2018","journal-title":"Protein Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658753","article-title":"Engineered TCR-T cell immunotherapy in anticancer precision medicine: Pros and cons. frontiers in immunology","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1146\/annurev.immunol.17.1.467","article-title":"THE DYNAMICS OF T CELL RECEPTOR SIGNALING: Complex orchestration and the key roles of tempo and cooperation","volume":"17","author":"Germain","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02250\/full","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000378","article-title":"T-Cell receptor\u2013based immunotherapy for hematologic malignancies","volume":"25","author":"Biernacki","year":"2019","journal-title":"Cancer J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","article-title":"Immunological mechanisms underneath the efficacy of cancer therapy","volume":"4","author":"Galluzzi","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032542","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PloS One"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0561-4","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Rodriguez-Ruiz","year":"2020","journal-title":"Nat Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differentiation"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx440.020","article-title":"KEYNOTE-059 update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G\/GEJ) cancer","volume":"28","author":"Wainberg","year":"2017","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-00909-5","article-title":"Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study","volume":"22","author":"Bang","year":"2019","journal-title":"Gastric Canc"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy540","article-title":"Safety and efficacy of nivolumab in combination with s-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)","volume":"30","author":"Boku","year":"2019","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"S1192","DOI":"10.1016\/j.annonc.2020.08.2297","article-title":"LBA7_PR nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric\/gastroesophageal junction (G\/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study","volume":"31","author":"Boku","year":"2020","journal-title":"Ann Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13797","article-title":"Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma","volume":"26","author":"Zhang","year":"2021","journal-title":"Oncologist."},{"key":"B95","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Intl J Canc"},{"key":"B97","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12885-022-09573-6","article-title":"Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 study)","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Canc"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2132","article-title":"LBA52 sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study","volume":"32","author":"Shen","year":"2021","journal-title":"Ann Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1479-5876-12-84","article-title":"Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients","volume":"12","author":"Iinuma","year":"2014","journal-title":"J Trans Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182619cb4","article-title":"Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer","volume":"35","author":"Fujiwara","year":"2012","journal-title":"J Immunother"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000155","article-title":"A dendritic cell vaccine combined with radiotherapy activates the specific immune response in patients with esophageal cancer","volume":"40","author":"Wang","year":"2017","journal-title":"J Immunother"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.02.002","article-title":"Adoptive \u03b3\u03b4T-cell transfer alone or combined with chemotherapy for the treatment of advanced esophageal cancer","volume":"23","author":"Sato","year":"2021","journal-title":"Cytotherapy."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013Small-Cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"New Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"JCO."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.12.02","article-title":"CheckMate-032 study: promising efficacy with nivolumab-based immunotherapy in pretreated esophagogastric cancer","volume":"11","author":"Sun","year":"2019","journal-title":"J Thorac Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00116-7","article-title":"Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial","volume":"3","author":"Ebert","year":"2022","journal-title":"Lancet Healthy Longevity"},{"key":"B110","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41392-020-00323-3","article-title":"Advances in targeted therapy for esophageal cancer","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B112","doi-asserted-by":"publisher","first-page":"100741","DOI":"10.1016\/j.xcrm.2022.100741","article-title":"PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer","volume":"3","author":"Wang","year":"2022","journal-title":"Cell Rep Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0310","article-title":"Safety and efficacy of apatinib monotherapy for unresectable, metastatic esophageal cancer: A single-arm, open-label, phase II study","volume":"25","author":"Yanwei","year":"2020","journal-title":"Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2021.0086","article-title":"Apatinib combined with paclitaxel and cisplatin neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma","volume":"37","author":"Zhao","year":"2022","journal-title":"Cancer Biother Radiopharmaceuticals"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13668","article-title":"A phase II study of apatinib in patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESO-shanghai 11)","volume":"26","author":"Chu","year":"2021","journal-title":"Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"7","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol Hepatology"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx002","article-title":"First-in-human phase 1 study of margetuximab (MGAH22), an fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors","volume":"28","author":"Bang","year":"2017","journal-title":"Ann Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30326-0","article-title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22\u201305): a single-arm, phase 1b\u20132 trial","volume":"21","author":"Catenacci","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1020290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T06:47:06Z","timestamp":1671086826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1020290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":118,"alternative-id":["10.3389\/fimmu.2022.1020290"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1020290","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"1020290"}}